NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAMS NEWAMSTERDAM PHARMA CO NV

Closed 09-28 16:00:00 EDT

23.58

+1.00

+4.43%

盘后23.58

+0.000.00%

19:30 EDT

High24.21	Low22.25	Vol2.06M
Open22.50	D1 Closing22.58	Amplitude8.68%
Mkt Cap2.82B	Tradable Cap2.14B	Total Shares119.54M
T/O48.56M	T/O Rate2.27%	Tradable Shares90.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAMS","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV","latestPrice":23.58,"timestamp":1790625600000,"preClose":22.58,"halted":0,"volume":2056742,"hourTrading":{"tag":"盘后","latestPrice":23.58,"preClose":23.58,"latestTime":"19:30 EDT","volume":8271,"amount":195037.32,"timestamp":1790638205333,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04428697962798937,"floatShares":90756826,"shares":119537169,"eps":-2.144229,"marketStatus":"Closed","change":1,"latestTime":"09-28 16:00:00 EDT","open":22.5,"high":24.21,"low":22.25,"amount":48559382.449152,"amplitude":0.086802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.144229,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790668800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":22.58,"preHourTrading":{"tag":"盘前","latestPrice":22.59,"preClose":22.58,"latestTime":"09:18 EDT","volume":2107,"amount":47563.889968,"timestamp":1790601524083,"change":0.01,"changeRate":0.000443,"amplitude":0.034925},"postHourTrading":{"tag":"盘后","latestPrice":23.58,"preClose":23.58,"latestTime":"19:30 EDT","volume":8271,"amount":195037.32,"timestamp":1790638205333,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.884589,"impliedVol":0.8275,"impliedVolPercentile":0.6813},"requestUrl":"/m/hq/s/NAMS/tweets","defaultTab":"tweets","newsList":[{"id":"2669627061","title":"Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco","url":"https://stock-news.laohu8.com/highlight/detail?id=2669627061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669627061?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:48","pubTimestamp":1790009307,"startTime":"0","endTime":"0","summary":"Sept 21 (Reuters) - NewAmsterdam Pharma Company N.V.::*MENARINI GROUP AND NEWAMSTERDAM PHARMA RECEIVE EUROPEAN COMMISSION APPROVAL FOR UBESLO (OBICETRAPIB MONOTHERAPY) AND EVLARCO (OBICETRAPIB PLUS EZ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nRSD5rJVRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162646","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162646?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:10","pubTimestamp":1790007009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN). NewAmster...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","HCSG","LU0128526141.USD","LABU","BK4137","NAMS","LPCN","BK4139","LU0029874061.USD","XLV","BK4588","BK4007","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169408","title":"NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169408","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169408?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:09","pubTimestamp":1789999795,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma (NAMS) said Monday that the European Commission approved Ubeslo, an obicetrapib monotherapy, and Evlarco, an obicetrapib-ezetimibe combination, for certain patients with elevated c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322673","title":"NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322673?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAMS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665232230","title":"Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665232230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665232230?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:50","pubTimestamp":1788864614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), NewAmsterdam Pharma Company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-newamsterdam-pharma-company-nams-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-newamsterdam-pharma-company-nams-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","BK4581","HCSG","BK4139","XLV","LU0128526141.USD","LU0029874061.USD","LABU","DYN","BK4588","BK4137","BK4505","IONS","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4139","LU0289739699.SGD","LU0211331839.USD","LU0109394709.USD","LU1061106388.HKD","LU2242652126.USD","BBH","LU0122379950.USD","BK4599","PBE","IBBQ","LU2089984988.USD","AMGN","LU0889565916.HKD","MEDX","NVS","LU1571399168.USD","BK4566","LU0070302665.USD","BIB","BK4588","LU0208291251.USD","BK4532","PPH","LU0320765489.SGD","PJP","LU0868494617.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4007","IE00BFTCPJ56.SGD","TBXU","BK4533","LU0320765992.SGD","LU1023059063.AUD","IBB","IE0009355771.USD","LU1983299246.USD","NAMS","BK4578","BK4585","BK4581","LU2112291526.USD","SG9999001440.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390614","title":"Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390614?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:11","pubTimestamp":1788768672,"startTime":"0","endTime":"0","summary":"UPDATE 2-Novartis cholesterol setback tests hopes for emerging heart disease drugsLONDON, Sept 7 (Reuters)-Shares of NovartisNOVN.Sfell more than 3% on Monday after its cholesterol drug failed in a cl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL1N44Z05O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0097036916.USD","PBE","OZEM","JDOC","MEDI","CURE","LU2089284900.SGD","BBH","IXJ","CANC","IHE","HRTS","TBXU","BIB","MHIP","VHT","LU0823434583.USD","NAMS","FHLC","TMED","XLV","IBB","LU2361044865.SGD","AMGN","ELIL","MEDX","LU1267930730.SGD","IE00BJJMRY28.SGD","THNR","PJP","FTXH","IBBQ","LU2750360641.GBP","WDNA","GDOC","TRUH","LLYX","LLYZ","AGNG","LU1571399168.USD","PPH","LU1691799644.USD","RXL","IYH","ELIS","SGXZ99366536.SGD","LLII","ILDR","LLY","SLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804794","title":"Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804794","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804794?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:46","pubTimestamp":1788471990,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - NewAmsterdam Pharma Company N.V.::*NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 03-SEP-202620:01:00.31 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nRSD2fFVfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664431809","title":"NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664431809","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664431809?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465686,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma grants inducement share options for 52,900 shares at $24.92 eachNewAmsterdam Pharma granted inducement share options for 52,900 ordinary shares under its 2024 Inducement Plan.Optio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5W5k7c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","NAMS","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662167677","title":"NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662167677","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662167677?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:03","pubTimestamp":1787745791,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026NewAmsterdam Pharma scheduled new analyses from its Phase 3 obicetrapib program for presentation at ESC Congress 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4m3BRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","NAMS","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4112","BK4585","IE00BKPKM429.USD","BCDF","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014039.USD","BK4139","IE00B64PRP62.GBP","SG9999014005.SGD","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662799719","title":"NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662799719","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662799719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:04","pubTimestamp":1787735040,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma CSO Johannes Kastelein disposes of 125,000 shares for USD 3.36 millionNewAmsterdam Pharma Chief Scientific Officer Johannes Jacob Pieter Kastelein reported a 125,000-share sale at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1SM4sM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129548","title":"NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129548","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129548?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:17","pubTimestamp":1786738639,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma amends 8-K to disclose COO Douglas Kling separation, advisor agreement termsNewAmsterdam Pharma amended a July 22, 2026 Form 8-K to disclose terms of Douglas Kling’s separation and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1bkhNf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659774126","title":"NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659774126","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659774126?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:09","pubTimestamp":1786738191,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma appoints Robert Gunning principal accounting officerNewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer, effective Aug. 10, 2026.Gunning joined as vice ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL5bdkw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","NAMS","BK4139","LU1878469433.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683621","title":"Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657683621?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:55","pubTimestamp":1786139738,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger maintained a Buy rating on NewAmsterdam Pharma Company today and set a price target of $48.00. Belanger covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657491","title":"NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657491?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:09","pubTimestamp":1786046997,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hiresNewAmsterdam Pharma issued inducement equity awards to three non-executive new hires under its 2024 Inducement Plan.Gra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9vL3yc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","LU2095319765.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014021.USD","BK4588","NAMS","SG9999014013.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","BCDF","IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657992634","title":"RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657992634","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657992634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:53","pubTimestamp":1786020824,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma (NAMS) has an average rating of buy and mean price target of $51.87, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657361816","title":"Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657361816","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657361816?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017676,"startTime":"0","endTime":"0","summary":"In a report released today, James Condulis from Stifel Nicolaus reiterated a Buy rating on NewAmsterdam Pharma Company, with a price target of $50....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAMS","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657421915","title":"NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657421915","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657421915?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:46","pubTimestamp":1785933984,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30 - Earnings SummaryNewAmsterdam Pharma Company N.V.NAMS.OQreported a quarterly adjusted loss of 52 cents per share for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4421WL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544754","title":"Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544754","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544754?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:27","pubTimestamp":1785932871,"startTime":"0","endTime":"0","summary":"Aug 5 (Reuters) - :*NEWAMSTERDAM PHARMA COMPANY N.V. - ANNOUNCES POSITIVE CHMP OPINION FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE*NEWAMSTERDAM PHARMA COMPANY N.V. - PREVAIL INTERIM ANALYSIS PLANNED FOR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nRSD7m4rXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657495375","title":"NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657495375","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657495375?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:25","pubTimestamp":1785929155,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60943990/newamsterdam-pharma-q2-eps-0-52-misses-0-48-estimate-sales-3-701m-beat-1-663m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":-0.1759},{"period":"3month","weight":-0.3207},{"period":"6month","weight":-0.2468},{"period":"1year","weight":-0.1411},{"period":"ytd","weight":-0.3563}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.163842},{"month":2,"riseRate":0.4,"avgChangeRate":0.036652},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017313},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.029307},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.010913},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.017361},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.019958},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.021568},{"month":9,"riseRate":0.666667,"avgChangeRate":0.000057},{"month":10,"riseRate":0.6,"avgChangeRate":0.067332},{"month":11,"riseRate":0.6,"avgChangeRate":0.02866},{"month":12,"riseRate":0.6,"avgChangeRate":0.126441}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV","nameEN":"NEWAMSTERDAM PHARMA CO NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEWAMSTERDAM PHARMA CO NV,NAMS,NEWAMSTERDAM PHARMA CO NV股票,NEWAMSTERDAM PHARMA CO NV股票老虎,NEWAMSTERDAM PHARMA CO NV股票老虎国际,NEWAMSTERDAM PHARMA CO NV行情,NEWAMSTERDAM PHARMA CO NV股票行情,NEWAMSTERDAM PHARMA CO NV股价,NEWAMSTERDAM PHARMA CO NV股市,NEWAMSTERDAM PHARMA CO NV股票价格,NEWAMSTERDAM PHARMA CO NV股票交易,NEWAMSTERDAM PHARMA CO NV股票购买,NEWAMSTERDAM PHARMA CO NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction